Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT05194735
PHASE1/PHASE2

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Sponsor: Alaunos Therapeutics

View on ClinicalTrials.gov

Summary

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors. The study ended during Phase I Arm A after 8 subjects were treated. Arm B and Phase II were not initiated, and the maximum tolerated dose or recommended Phase II dose was not determined.

Official title: Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

8

Start Date

2022-04-04

Completion Date

2023-10-11

Last Updated

2026-11-09

Healthy Volunteers

No

Interventions

BIOLOGICAL

Neoantigen specific TCR-T cell drug product

Phase I: Ascending dose, single Infusion of TCR+ Cells Phase II: Single infusion at the RP2D

BIOLOGICAL

Aldesleukin (IL-2)

To support growth and activation of TCR-T cell drug product

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States